» Articles » PMID: 39360065

Utilizing Multifaceted Approaches to Target Drug Delivery in the Brain: From Nanoparticles to Biological Therapies

Overview
Journal Cureus
Date 2024 Oct 3
PMID 39360065
Authors
Affiliations
Soon will be listed here.
Abstract

The blood-brain barrier (BBB) poses an important obstacle to treating neurological disorders because it limits the entry of therapeutic agents into the central nervous system (CNS). Surmounting this barrier is crucial for delivering drugs effectively and targeting precise areas of the brain affected by conditions like Parkinson's disease, Alzheimer's disease, and brain tumors. This review examines the diverse strategies employed to enhance brain targeting, including nanotechnology, viral vectors, and biological therapies. Nanoparticles, liposomes, and dendrimers offer promising approaches for encapsulating drugs and facilitating their transport across the BBB. Viral vectors, such as adeno-associated viruses, demonstrate high transfection efficiency for gene therapy applications in CNS diseases. Biological therapies, including stem cell transplantation and neuromodulation techniques, can potentially restore normal cellular function and treat genetic disorders. Challenges such as BBB permeability, safety concerns, and regulatory considerations are discussed, along with future perspectives on precision medicine, noninvasive delivery methods, and biomarker discovery. By addressing these challenges and embracing innovative approaches, the field of brain drug targeting aims to transfer the way that neurological illness is treated and improve patient outcomes.

Citing Articles

Artificial intelligence-driven prediction and validation of blood-brain barrier permeability and absorption, distribution, metabolism, excretion profiles in natural product research laboratory compounds.

Yang J, Huang E, Liao K, Bau D, Tsai S, Chen C Biomedicine (Taipei). 2025; 14(4):82-91.

PMID: 39777113 PMC: 11703399. DOI: 10.37796/2211-8039.1474.


Special Issue "Mechanisms and Novel Therapeutic Approaches for Neurodegenerative Diseases".

Cardona F Biomedicines. 2024; 12(11).

PMID: 39595127 PMC: 11591635. DOI: 10.3390/biomedicines12112554.

References
1.
He Q, Liu J, Liang J, Liu X, Li W, Liu Z . Towards Improvements for Penetrating the Blood-Brain Barrier-Recent Progress from a Material and Pharmaceutical Perspective. Cells. 2018; 7(4). PMC: 5946101. DOI: 10.3390/cells7040024. View

2.
Sharma G, Sharma A, Nam J, Doss G, Lee S, Chakraborty C . Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. J Nanobiotechnology. 2015; 13:74. PMC: 4619439. DOI: 10.1186/s12951-015-0136-y. View

3.
Wong K, Xie Y, Huang X, Kadota K, Yao X, Yu Y . Delivering Crocetin across the Blood-Brain Barrier by Using γ-Cyclodextrin to Treat Alzheimer's Disease. Sci Rep. 2020; 10(1):3654. PMC: 7046745. DOI: 10.1038/s41598-020-60293-y. View

4.
Liebner S, Czupalla C, Wolburg H . Current concepts of blood-brain barrier development. Int J Dev Biol. 2011; 55(4-5):467-76. DOI: 10.1387/ijdb.103224sl. View

5.
Zhang W, Smith C, Shapiro A, Monette R, Hutchison J, Stanimirovic D . Increased expression of bioactive chemokines in human cerebromicrovascular endothelial cells and astrocytes subjected to simulated ischemia in vitro. J Neuroimmunol. 1999; 101(2):148-60. DOI: 10.1016/s0165-5728(99)00137-x. View